Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial.
- DOI
- 10.1016/j.jtho.2026.104062
- Published
- 2026 Jun 24
- Container
- Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtho.2026.104062,
title = {Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial.},
author = {Li Z and Yao B and Huang C and Xie C and Guo R and Feng J and Yao W and Huang H and Li Y and Pan Y and Lu S},
year = {2026},
journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
doi = {10.1016/j.jtho.2026.104062},
url = {https://doi.org/10.1016/j.jtho.2026.104062}
}RIS
TY - JOUR TI - Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial. AU - Li Z AU - Yao B AU - Huang C AU - Xie C AU - Guo R AU - Feng J AU - Yao W AU - Huang H AU - Li Y AU - Pan Y AU - Lu S PY - 2026 JO - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer DO - 10.1016/j.jtho.2026.104062 UR - https://doi.org/10.1016/j.jtho.2026.104062 ER -
APA
Z, L., B, Y., C, H., C, X., R, G., J, F., W, Y., H, H., Y, L., Y, P., & S, L. (2026). Brief Report: Aumolertinib as a Switch Therapy in Osimertinib-Intolerant NSCLC-The ACTIVE Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2026.104062
Source records
- pubmed · retrieved 2026-09-26T17:35:43.311Z